You are here


Fareston is an antiestrogenic drug that is used as a hormone therapy. Encoding ATC: L02B A02.


L02BA02 Toremifene

Indications of fareston

Fareston is used as a primary drug in the treatment protocol with metastatic cancer in the mammary gland in postmenopausal.

Furthermore, the drug can be administered for prophylactic and therapeutic purposes in dyshormonal dysplasia of the breast.

Fareston not estrogenretseptornegativnyh used to treat neoplasms.

Release form

Fareston is released in tablets of 20 or 60 mg. Tablets are flat-rounded, light shade, with one-sided inscription TO 20 or TO 60 (which corresponds to the dosage of the drug).

The active ingredient of Fareston is toremifene citrate.

Tablets are packed in bottles of 30 pcs. Pack of cardboard, with instructions for use inside.


The active ingredient toremifene is a representative of triphenylethylene and has the property of contacting with estrogen receptors and producing a similar or anti-estrogenic effect. At the same time, there is a slight decrease in the serum cholesterol level.

Fareston forms a bond with estrogen receptors and blocks the indirect activation of DNA production and the process of cell replication. Studies have confirmed the estrogen-independent anti-cancer effect of the drug.

It is assumed that at the moment, not all the links of the anti-cancer effect of Fareston have been studied. Probably, treatment with a drug provokes changes in oncogenic expression, affects the kinetic properties of the cell cycle, etc.


Fareston is well absorbed in the body. The limiting level of the active ingredient in the blood serum is determined after 2-5 hours. The presence of food masses in the stomach does not affect the absorption of the drug, but the limit level can be shifted by 90-120 minutes, although this fact has no therapeutic value.

The connection with plasma proteins is noted at 99.5%.

The metabolism of the active ingredient is quite intense. Excretion from the body takes place in the form of residual products with caloric masses, and only up to 10% is excreted by the kidneys.

The stable level of the drug in the blood is noted for about 5 weeks.

Use of fareston during pregnancy

Phareston is prescribed to patients in the postmenopausal period, so its use in pregnancy and breastfeeding is not considered or is considered impractical.


Absolute contraindication to the reception of Fareston is considered endometrial hyperplasia and insufficient liver function.

In addition, Fareston is not appointed:

  • with a possible allergy to the drug;
  • with cardiac pathologies accompanied by an elongation of the QT interval;
  • in disorders of water balance with incorrect hypokalemia;
  • with severe bradycardia;
  • with cardiac pathologies, which are accompanied by a decrease in left ventricular ejection;
  • with symptomatic heart rhythm disturbances.

Side effects of fareston

Adverse reactions while taking Fareston are not uncommon. You may experience the following symptoms:

  • a sense of "tide", which are accompanied by sweating and redness of the face;
  • bleeding and vaginal discharge;
  • feeling tired;
  • nausea, dizziness;
  • edema, weight gain;
  • thrombosis, thrombophlebitis;
  • skin rashes;
  • depression;
  • hypertrophy of endometrial hyperplasia, polyps, cancerous growths.

Dosing and administration

Phareston is taken orally, at any time, without communication with food intake.

  • For dyshormonal dysplasia of the breast, 20 g of preparation per day are prescribed.
  • With estrogen-dependent breast cancer, 60 mg per day is prescribed.
  • With insufficient kidney function, dosage adjustment is not required.
  • With insufficient liver function, Fareston is prescribed very carefully, and the dosage is selected individually.


 Overdose Fareston may be accompanied by:

  • dizziness;
  • pain in the head;
  • loss of balance.

Treatment is prescribed according to the detected symptoms, since there is no special drug for eliminating overdose phenomena.

Interactions with other drugs

It is forbidden simultaneous reception of Phareston and the following medicines:

  • antiarrhythmic drugs;
  • antipsychotics;
  • Erythromycin, moxifloxacin, antimalarial drugs, Pentamidine;
  • antihistamines Terfenadine or Misolastine;
  •  Difemannil, Vinkamina and other medications that can prolong the QT interval.

 In addition, other combinations of Fareston should be avoided:

  • with thiazide diuretics (due to the development of hypercalcemia);
  • with Phenobarbital, carbamazepine (due to the probability of a decrease in the level of toremifene in the bloodstream);
  • with antiestrogens and anticoagulants (because of the possibility of bleeding);
  • with ketoconazole, antimycotics, macrolide antibiotics (due to inhibition of the metabolic processes of toremifene).

Storage conditions

Fareston is kept in a room environment, excluding children's access to storage facilities for medicines.

Shelf life

Fareston is allowed to store up to 5 years.

Found an error? Select it and press Ctrl + Enter.

Share on social networks


To simplify the perception of information, this instruction for use of the drug "Fareston" translated and presented in a special form on the basis of the official instructions for medical use of the drug. Before use read the annotation that came directly to medicines.

Description provided for informational purposes and is not a guide to self-healing. The need for this drug, the purpose of the treatment regimen, methods and dose of the drug is determined solely by the attending physician. Self-medication is dangerous for your health.

You are reporting a typo in the following text:
Simply click the "Send typo report" button to complete the report. You can also include a comment.